AAPS PharmSciTech

, Volume 7, Issue 1, pp E1–E9 | Cite as

Formulation and in vitro, in vivo evaluation of extended- release matrix tablet of Zidovudine: Influence of combination of hydrophilic and hydrophobic matrix formers

  • Atul Kuksal
  • Ashok K. Tiwary
  • Narendra K. Jain
  • Subheet Jain
Article

Abstract

The aim of the present study was to prepare and characterize extended-release matrix tablets of zidovudine using hydrophilic Eudragit RLPO and RSPO alone or their combination with hydrophobic ethyl cellulose. Release kinetics was evaluated by using United States Pharmacopeia (USP)-22 type I dissolution apparatus. Scanning electron microscopy was used to visualize the effect of dissolution medium on matrix tablet surface. Furthermore, the in vitro and in vivo newly formulated sustained-release zidovudine tablets were compared with conventional marketed tablet (Zidovir, Cipla Ltd, Mumbai, India). The in-vitro drug release study revealed that either Eudragit preparation was able to sustain the drug release only for 6 hours (94.3%±4.5% release). Combining Eudragit with ethyl cellulose sustained the drug release for 12 hours (88.1%±4.1% release). Fitting the in vitro drug release data to Korsmeyer equation indicated that diffusion along with erosion could be the mechanism of drug release. In vivo investigation in rabbits showed sustained-release pharmacokinetic profile of zidovudine from the matrix tablets formulated using combination of Eudragits and ethylcellulose. In conclusion, the results suggest that the developed sustained-release tablets of zidovudine could perform therapeutically better than conventional dosage forms, leading to improve efficacy and better patient compliance.

Keywords

anti-HIV drug Zidovudine matrix tablets sustained release mechanism scanning electron microscopy 

References

  1. 1.
    Chien YW, Wearley LL. AIDS and chemotherapy. Drugs Today. 1989;25:19–25.Google Scholar
  2. 2.
    Jain S, Umamaheshwari RB, Bhadra D, Jain NK. Ethosomes: a novel vesicular carrier for enhanced transdermal delivery of an anti-HIV agent. Ind J Pharm Sci. 2004;66:72–81.Google Scholar
  3. 3.
    Jain S, Tiwary AK, Jain NK. Transdermal delivery of an anti-HIV agent using elastic liposomes: mechanism of action., Curr Drug Deliv. In press.Google Scholar
  4. 4.
    Kieburtz KD, Seidllin M, Lambert JS, Dollis R, Reichman R, Valentine T. Extended follow-up of neuropathy in patients with AIDS and AIDS related complex treated with dideoxyinosine. J Acquir Immuno Defic Syndrom. 1992;5:60–64.Google Scholar
  5. 5.
    Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′ azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related disease. Clin Pharmacol Ther. 1987;41:407–412.CrossRefPubMedGoogle Scholar
  6. 6.
    Salsa T, Veiga F, Pina ME. Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm. 1997;23:929–938.CrossRefGoogle Scholar
  7. 7.
    Sanchez-Lafuente C, Furlanetto S, Fernandez-Arevalo M, et al. Didanosine extended release matrix tablets: optimization of formulation variables using statistical experimental design. Int J Pharm. 2002; 237:107–118.CrossRefPubMedGoogle Scholar
  8. 8.
    Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Tech Prod Mfr. 1984;5:1–9.Google Scholar
  9. 9.
    Gohel MC, Patel TP, Bariya SH. Studies in preparation and evaluation of pH independent sustained-release matrix tablets of verapamil HCl using directly compressible Eudragits. Pharm Dev Technol. 2003;8:323–333.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu J, Zhang F, McGinity JW. Properties of lipophilic matrix tablets containing phenylpropanolamine hydrochloride prepared by hot-melt extrusion. Eur J Pharm Biopharm. 2001;52:181–190.CrossRefPubMedGoogle Scholar
  11. 11.
    Bettini R, Colombo P, Massimo G, Catellani PL, Vitali T. Swelling and drug release in hydrogel matrices: polymer viscosity and matrix porosity effects. Eur J Pharm Sci. 1994;2:213–219.CrossRefGoogle Scholar
  12. 12.
    Reddy KR, Mutalik S, Reddy S. Once daily sustained release matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS Pharm Sci Tech. 2003;4:E61.CrossRefGoogle Scholar
  13. 13.
    Aulton ME, Wells TI. Pharmaceutics: The Science of Dosage Form Design. London, UK: Churchill Livingstone; 1988.Google Scholar
  14. 14.
    Government of India Ministry of Health and Family Welfare. The Pharmacopoeia of India. Delhi, India: Controller of Publication; 1996.Google Scholar
  15. 15.
    Higuchi T. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149.CrossRefPubMedGoogle Scholar
  16. 16.
    Korsmeyer RW, Gurny R, Docler E, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.CrossRefGoogle Scholar
  17. 17.
    Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110–111.PubMedGoogle Scholar
  18. 18.
    Mockel JE, Lippold BC. Zero order release from hydrocolloid matrices. Pharm Res. 1993;10:1066–1070.CrossRefPubMedGoogle Scholar
  19. 19.
    Al-Taani BM, Tashtoush BM. Effect of microenvironment pH of swellable and erodable buffered matrices on the release characteristics of diclofenac sodium. AAPS Pharm Sci Tech. 2003;4:E43.CrossRefGoogle Scholar
  20. 20.
    Pereira AS, Kenney KB, Cohen MS, et al Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000;742:173–183.CrossRefPubMedGoogle Scholar
  21. 21.
    Ebube NK, Hikal A, Wyandt CM, Beer DC, Miller LG, Jones AB. Sustained release of acetaminophen from heterogeneous matrix tablets, influence of polymer ratio, polymer loading and coactive on drug release. Pharm Dev Technol. 1997;2:161–170.CrossRefPubMedGoogle Scholar
  22. 22.
    Blum MR, Liao SHT, Good SS, De Miranda P. Pharmacokinetic and bioavailability of zidovudine in human. Am. J Med. 1988;85: 189–194.CrossRefPubMedGoogle Scholar
  23. 23.
    Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. N Engl J Med. 1987;317:192–197.CrossRefPubMedGoogle Scholar
  24. 24.
    Katikaneni PR, Upadrashia SM, Neau SH, Mitra AK. Ethylcellulose matrix controlled-release tablets of a water soluble drug. Int J Pharm. 1995;123:119–125.CrossRefGoogle Scholar
  25. 25.
    Efentakis M, Koutlis A. Release of furosemide from multiple unit and single unit preparations containing different viscosity grades of sodium alginate. Pharm Dev Technol. 2001;6:91–98.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2006

Authors and Affiliations

  • Atul Kuksal
    • 1
  • Ashok K. Tiwary
    • 1
  • Narendra K. Jain
    • 2
  • Subheet Jain
    • 1
  1. 1.Department of Pharmaceutical Sciences and Drug ResearchPunjabi UniversityPatialaIndia
  2. 2.Department of Pharmaceutical SciencesDr Hari Singh Gour UniversitySagarIndia

Personalised recommendations